A comprehensive view of Approval Recommendations. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Novavax Inc. - Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall
Published:
April 26, 2024
by U.S. Markets (Alternative Disclosure) via PUBT
|
CHMP recommends EU approval of Roche’s Alecensa monotherapy as the first adjuvant treatment for resected ALK-positive early-stage lung cancer; about half of people living with early-stage NSCLC experiencing disease recurrence or death following surgery
Published:
April 26, 2024
by F. Hoffmann-La Roche Ltd. (Roche)
|
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall
Published:
April 26, 2024
by Novavax Inc.
|
CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo nivolumab in combination with Cisplatin and Gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Published:
April 26, 2024
by Bristol-Myers Squibb Co.
|
BIOGEN INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Published:
April 24, 2024
by SEC Edgar Filings
|
Ask us about our Tissue & Hygiene market view